MedTrace Logo

First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors

NCT01469052 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2012-03-26

Study results available
· View outcomes & findings →

Summary

The purpose of the study was to characterize the safety of investigational agent AG-013736, in patients with solid tumors in this First In Human trial.

Conditions

Interventions

DRUG

AG-013736

Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state

DRUG

AG-013736

Axitinib continuous oral dosing (20 mg twice a day) in the fed state

DRUG

AG-013736

Axitinib continuous oral dosing (5 mg twice a day) in the fed state

DRUG

AG-013736

Axitinib continuous oral dosing (15 mg once a day) in the fed state

DRUG

AG-013736

Axitinib continuous oral dosing (5 mg twice a day) in the fasted state

DRUG

AG-013736

Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2004-07-31
Completion
2004-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01469052 on ClinicalTrials.gov